Journal of Urgent Care Medicine

New Gastroparesis Guidelines Focus on First-Line Treatments

A new clinical practice guideline from the American Gastroenterological Association helps support physicians who are treating patients with gastroparesis. The condition is difficult to diagnose and treat, so the new guidelines outline the current state of the evidence for clinical options, as published in Gastroenterology. Part of the motivation for publishing the insight comes from possible new risks for gastroparesis related to glucagon-like peptide-1 (GLP-1) receptor agonists that are increasingly being used by patients for …

GLP-1 Drugs Increase Risk of Macular Degeneration

A recent study in JAMA Network Ophthalmology found that older adults with diabetes who were treated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) had a significantly higher risk of developing neovascular age-related macular degeneration (nAMD). The retrospective study, conducted from January 2020 to November 2023, followed patients for up to 3 years. It included individuals aged 66 years or older (46.6% female) who had a diagnosis of diabetes and at least 12 months of follow-up …

Trends Show More Teens Prescribed Weight Loss Drugs

Use of semaglutide for weight loss among American teens is rising with new prescriptions increasing significantly, according to an analysis of 1.3 million electronic health records by Truveta and Reuters. The rate climbed from 9.9 prescriptions per 100,000 teens in 2023 to 14.8 in 2024. The average rate climbed further during the first 3 months of this year, reaching 17.3 new prescriptions per 100,000, according to Reuters. This growth also follows the American Academy of …

GLP-1 Drugs May Have Potential For Addiction Treatment

Patients taking glucagon-like peptide-1 (GLP-1) drugs like semaglutide for diabetes may have a lower risk of opioid drug overdose, according to a new study led by National Institute on Drug Abuse Director Nora Volkow, MD, published in JAMA Network Open. Previous empirical studies and anecdotal reports of fewer drug cravings among individuals with type 2 diabetes and comorbid opioid use disorder who use semaglutide inspired the study. Because the GLP-1 drugs are relatively new, there …

Liraglutide May Help Kids Under 12 Lose Weight

Liraglutide, the long-acting glucagon-like peptide-1 (GLP-1) drug, was approved for weight loss in among pediatric patients aged 12 and older who are obese. Recently, manufacturer Novo Nordisk found in a sponsored study that children between the ages of 6 and 12—a younger population—were able to reduce their body mass index by 7.4% in a 56-week trial using daily liraglutide injections, as published in the New England Journal of Medicine. The trial of 92 children met …

Login to JUCM